YICHANG HEC CHANGJIANG PHARMACEUTICAL CO., LTD.

Other languages YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

Equities

1558

CNE1000023R6

Delayed Hong Kong S.E. Other stock markets 23:24:33 2024-04-28 EDT			5-day change	1st Jan Change
12.98 ^HKD	+1.41%		+8.53%	+36.78%

04-09	Yichang Hec Changjiang Pharmaceutical Updates on Possible Merger with Sunshine Lake Pharma	MT
04-01	Yichang Hec Changjiang Pharmaceutical's Net Profit Surges in 2023 as Revenue Jumps	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Yichang Hec Changjiang Pharmaceutical Updates on Possible Merger with Sunshine Lake Pharma	04-09
Yichang Hec Changjiang Pharmaceutical's Net Profit Surges in 2023 as Revenue Jumps	03-31
YiChang HEC ChangJiang Pharmaceutical's Profit Surges in 2023	03-28
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28
Yichang Hec Changjiang Pharmaceutical Expects Up to 2,627% Profit Surge in 2023	03-12
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Provides Group Earnings Guidance for the Year Ended 31 December 2023	03-12
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. and Sunshine Lake Pharma Enter into Drug R&D Pipeline Cooperation Project Framework Agreement	11-29
HEC ChangJiang Pharmaceutical Increases Transaction Limits Under 2 Contracts	11-08
HEC ChangJiang Pharmaceutical's Insulin Injection Cleared for Market Launch in China	23-09-26
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Receives Approval for Mixed Protamine Human Insulin Injection from the China National Medical Products Administration	23-09-25
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.Approves Announces Executive Changes	23-09-08
HEC ChangJiang Pharmaceutical Returns to Profit on Surge in Anti-Viral Drug Sales	23-09-01
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31
China Greenlights New Drug Application for HEC ChangJiang Pharmaceutical's Hepatitis C Drug	23-08-16
National Medical Products Administration of the People's Republic of China Accepts the Application for Launching Yiqibuvir Tablets	23-08-15
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Announces Resignation of Chen Yangui as Executive Director	23-08-14
HEC ChangJiang Pharmaceutical Forecasts Surge in H1 Profit; Shares Rise 5%	23-07-27
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2023	23-07-26
HEC ChangJiang Pharma Repurchases $400 Million Convertible Bonds Issued to Blackstone	23-07-06
HEC Chang Jiang Pharma Completes Equity Transfer in Unit	23-06-28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

Equities

1558

CNE1000023R6

Other languages

Filters